Sanofi trumpets data with haemophilia treatment duo at ISTH

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at th

Sanofi/Alnylam's haemophilia drug hits another safety speed-...

Sanofi’s attempt to take on Roche with a ground-breaking approach to treating haemophilia has hit a setback after the company voluntarily placed its late-stage trials of fitusiran on hold b

Novo Nordisk builds in haemophilia with Bluebird Bio gene ed...

NHS reimburses Roche's Hemlibra in new group of haemophilia ...

NHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, widening access to the potentially life-saving drug.

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...

BioMarin seeks haemophilia gene therapy approval after promi...

BioMarin is set to file for approval for its haemophilia gene therapy valoctocogene roxaparvovec, after it achieved pre-specified clinical criteria for regulatory review.